Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | President and CFO | April 03, 2023 | April 05, 2023 |
| Q32 Bio Inc.QTTB · Entity 5594 | CFO and President | October 06, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 30,309 |
Reported balance
After 2023-04-03 transaction · row 1
1 source rowRow 1 · 2023-04-03 · Sale · Disposed 376 · Balance 30,309 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Q32 Bio Inc.
Report date October 06, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,170 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 1,301 · Balance 137,170 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 14, 2026 21:30 UTC | Q32 Bio Inc. QTTB · Entity 5594 | SaleCommon Stock | 1,301 | $8.32 | $10,824.06 |
DisclosureSEC source: 0001193125-26-421834 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,170 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.08 to $8.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:10 UTC | Q32 Bio Inc. QTTB · Entity 5594 | SaleCommon Stock | 3,972 | $16.56 | $65,776.32 |
DisclosureSEC source: 0001193125-26-371293 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,471 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| July 16, 2026 Filed Jul 21, 2026 01:25 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantCommon Stock | 53,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-309324 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,443 F1 · kind: Represents shares of Issuer common stock underlying performance-based restricted stock units ("PSUs") granted on July 6, 2026, which vested on July 16, 2026 with respect to a performance-based condition, upon achievement of the closing of a financing of at least $100,000,000 in gross proceeds on or before December 31, 2026. Such PSUs are also subject to a time-based condition, which provides that the PSUs shall vest in equal quarterly installments over three years from July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Each PSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 25, 2026 Filed Feb 28, 2026 00:00 UTC | Q32 Bio Inc. QTTB · Entity 5594 | SaleCommon Stock | 3,995 | $4.51 | $18,035.03 |
DisclosureSEC source: 0001193125-26-083588 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,943 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 24, 2026 Filed Mar 20, 2026 23:00 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantCommon Stock | 53,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118052 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,193 F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:00 UTC | Q32 Bio Inc. QTTB · Entity 5594 | SaleCommon Stock | 9,072 | $3.46 | $31,395.47 |
DisclosureSEC source: 0001193125-25-308327 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,938 Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 23:20 UTC | Q32 Bio Inc. QTTB · Entity 5594 | SaleCommon Stock | 4,240 | $1.80 | $7,636.24 |
DisclosureSEC source: 0001193125-25-191442 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,010 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions over two consecutive trading days, at per share prices ranging from $1.81 to $1.96 and $1.73 to $1.83, respectively. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 2. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 161,323 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 5 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,323 Underlying: Common Stock · 161,323 shares Expires 2033-10-12 F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 161,323 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 4 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 161,323 shares Expires 2033-10-12 F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 16,901 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,901 Underlying: Common Stock · 16,901 shares Expires 2033-11-08 F4 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,901 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0000950170-25-028269 · ownership.xml · derivative · entry 2 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,901 shares Expires 2033-11-08 F2 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantCommon Stock | 53,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028269 · ownership.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,250 F1 · kind: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:34 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 161,323 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-24-037383 · ownership.xml · derivative · entry 1 Kalowski Lee · CIK 0001618273 · CFO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,323 Underlying: Common Stock · 161,323 shares Expires 2033-10-12 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 13, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:41 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 376 | $21.11 | $7,937.36 |
DisclosureSEC source: 0001209191-23-023347 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,309 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $21.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-23-002190 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2033-01-03 F5 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,815 | $29.06 | $52,743.90 |
DisclosureSEC source: 0001209191-23-002190 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,685 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002190 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $60.87 | $0.00 |
DisclosureSEC source: 0001209191-22-001811 · doc4.xml · derivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2023 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001811 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2023 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:49 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001209191-21-054792 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 10,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 2, 2021 and the remaining shares in 36 equal monthly installments at the end of each calendar month thereafter. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:49 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-21-054792 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:49 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 10,000 | $9.82 | $98,200.00 |
DisclosureSEC source: 0001209191-21-054792 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 22:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,950 | $0.00 Strike: $8.73 | $0.00 |
DisclosureSEC source: 0001209191-21-053710 · doc4.xml · derivative · entry 6 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,768 Underlying: Ordinary Shares · 7,950 shares Expires 2029-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3709 to GBP 1.00 as of August 27, 2021. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: 25% of the shares vested on January 1, 2020, and the remaining vested or shall vest in 36 equal monthly installments. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 22:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 7,950 | $35.15 | $279,442.50 |
DisclosureSEC source: 0001209191-21-053710 · doc4.xml · nonDerivative · entry 4 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.08 to $35.18 inclusive. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 22:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 7,950 | $8.73 | $69,403.50 |
DisclosureSEC source: 0001209191-21-053710 · doc4.xml · nonDerivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F4 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3709 to GBP 1.00 as of August 27, 2021. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 22:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001209191-21-053710 · doc4.xml · derivative · entry 5 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,718 Underlying: Ordinary Shares · 550 shares Expires 2029-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.374675 to GBP 1.00 as of August 26, 2021. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: 25% of the shares vested on January 1, 2020, and the remaining vested or shall vest in 36 equal monthly installments. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 22:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 550 | $35.04 | $19,272.00 |
DisclosureSEC source: 0001209191-21-053710 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $35.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (5). Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 22:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 550 | $8.76 | $4,818.00 |
DisclosureSEC source: 0001209191-21-053710 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.374675 to GBP 1.00 as of August 26, 2021. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-21-053350 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,774 Underlying: Ordinary Shares · 7,500 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 7,500 | $33.02 | $247,650.00 |
DisclosureSEC source: 0001209191-21-053350 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.056 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 21:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 7,500 | $1.60 | $12,000.00 |
DisclosureSEC source: 0001209191-21-053350 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 22:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-21-048919 · doc4.xml · derivative · entry 5 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,274 Underlying: Ordinary Shares · 12,500 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39511 to GBP 1.00 as of July 29, 2021. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 22:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 300 | $32.81 | $9,843.00 |
DisclosureSEC source: 0001209191-21-048919 · doc4.xml · nonDerivative · entry 4 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.78 to $32.86 inclusive. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 22:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,204 | $32.13 | $102,944.52 |
DisclosureSEC source: 0001209191-21-048919 · doc4.xml · nonDerivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.77 to $32.76 inclusive. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 22:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 8,996 | $31.24 | $281,035.04 |
DisclosureSEC source: 0001209191-21-048919 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,504 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 to $31.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5). Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 22:21 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 12,500 | $1.63 | $20,375.00 |
DisclosureSEC source: 0001209191-21-048919 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39511 to GBP 1.00 as of July 29, 2021. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:29 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-21-004665 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,774 Underlying: Ordinary Shares · 15,000 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.36076 to GBP 1.00 as of January 19, 2021. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:29 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 15,000 | $30.00 | $450,000.00 |
DisclosureSEC source: 0001209191-21-004665 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:29 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 15,000 | $1.59 | $23,850.00 |
DisclosureSEC source: 0001209191-21-004665 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.36076 to GBP 1.00 as of January 19, 2021. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:44 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-21-003826 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,774 Underlying: Ordinary Shares · 10,000 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.36521 to GBP 1.00 as of January 14, 2021. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:44 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001209191-21-003826 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:44 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001209191-21-003826 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.36521 to GBP 1.00 as of January 14, 2021. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:33 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 70,500 | $0.00 Strike: $17.95 | $0.00 |
DisclosureSEC source: 0001209191-21-001359 · doc4.xml · derivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,500 Underlying: Common Stock · 70,500 shares Expires 2031-01-04 F1 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares under option on January 4, 2022 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:53 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-20-061720 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,774 Underlying: Ordinary Shares · 7,500 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33547 to GBP 1.00 as of December 1, 2020. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:53 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 7,500 | $22.50 | $168,750.00 |
DisclosureSEC source: 0001209191-20-061720 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:53 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 7,500 | $1.56 | $11,700.00 |
DisclosureSEC source: 0001209191-20-061720 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33547 to GBP 1.00 as of December 1, 2020. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 21:42 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 530 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-20-060741 · doc4.xml · derivative · entry 3 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,274 Underlying: Ordinary Shares · 530 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33582 to GBP 1.00 as of November 27, 2020. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 21:42 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 530 | $20.00 | $10,600.00 |
DisclosureSEC source: 0001209191-20-060741 · doc4.xml · nonDerivative · entry 2 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 21:42 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionOrdinary Shares | 530 | $1.56 | $826.80 |
DisclosureSEC source: 0001209191-20-060741 · doc4.xml · nonDerivative · entry 1 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33582 to GBP 1.00 as of November 27, 2020. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 01:31 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,781 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-20-060598 · doc4.xml · derivative · entry 7 Kalowski Lee · CIK 0001618273 · President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,804 Underlying: Ordinary Shares · 9,781 shares Expires 2027-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.33434 to GBP 1.00 as of November 25, 2020. F1 · kind: Shares exercised and sold pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.